InnoCare Pharma reported revenue of 1.14 billion yuan ($168 million) for the first half of 2026, an increase of 55.5 percent from a year earlier, as sales of its medicines continued to grow.
The Beijing-based biotech company made a net profit of 239.7 million yuan during the period, reversing a loss of 36 million yuan in the first half of 2025.
Drug sales increased 43.2 percent to 918.1 million yuan and contributed more than 80 percent of total revenue. InnoCare said sales were lifted by wider use of orelabrutinib, a novel therapy for cancers and autoimmune diseases, including for the first-line treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma, as well as the launches of tafasitamab and zurletrectinib, two cancer drugs.
The company spent 497.1 million yuan on research and development, up 10.5 percent year-on-year. It had about 8.4 billion yuan in cash and related accounts at the end of June and recorded positive operating cash flow.
Two of its Phase III trials also reached their main goals during the period. Orelabrutinib was also approved in Australia for relapsed or refractory mantle cell lymphoma.
Jasmine Cui, co-founder, chairwoman and CEO of InnoCare, said the company would continue to expand sales while moving its drug candidates through clinical development.
InnoCare expects its drug sales to grow by more than 35 percent in 2026 and said it expects to remain profitable for the full year.
Yu Guo contributed to this story.
